The Clinical Research Of WD-5 With Biological Response Modifiers With IFN-α2b & IL-2 In Treatment Of Renal Cell Carcinoma Patients Of Stage Ⅲ,Ⅳ

Object:Using the RECIST(Response Evaluation Critera In Solid Tumors) criteria to elaluate the effect of traditional Chinese medicine(WD-5) and biological response modifiers with IL-2 & IFN-α2b on renal cell cancer patients of stageⅢ,Ⅳ.Also assessing the clinical evaluating indexes such as clinical symptom amelioration, Karnofsky score, tumor marks, The T lymphocyte subsets and the quality of life(QOL). The safety was evaluated according to NCI CTC 3.0 version criteria. Thereby to provide the clinical evidence to spread using WD-5 and evaluate the effect of traditional Chinese medicine impersonally and veritably.Methods:40 renal cell carcinoma cases of stageⅢ,Ⅳconfirmed by histopathology or cytopathology were randomly assigned into 2 groups. According to random number table, enlisted patients were divided into observation group and control group.The combined treated group were given WD-5 and biological response modifiers with IL-2 & IFN-α2b, and the control group were treated with biological response modifiers with IL-2 & IFN-α2b scheme only.6 weeks is a treatment course. The efficacy was evaluated after 2 courses according to RECIST (Response Evaluation Critera In Solid Tumors) criteria, and the clinical evaluating indexes such as clinical symptom amelioration, Karnofsky score, tumor marks, The T lymphocyte subsets and the quality of life (QOL) and the toxicity and feasible with tolerable adverse reactions.Result:Comparing the tumour weights after treatment, the response rates in the 2 groups were 20% and 15%, respectively, while the disease control rate were 55% and 40%, there was no significant difference between the two groups (P>0.05). The trail group displayed more effective lightening the clinical symptoms, enhancing the quality of life and the physical strength (KPS score), improving immunologic function, reducing the level of tumor marker, raising patients' quality of life and reducing toxicity. Showing significant difference between the two groups (P<0.05)Conclusion:In this research WD-5 and biological response modifiers with IL-2 & IFN-α2b can lightening the clinical symptoms, enhancing the quality of life, improving the immunologic function, reducing the level of tumor marker, raising patients'quality of life and reducing the toxicity and feasible with tolerable adverse reactions. It can be an important method of comprehensive therapy. It is worthy of further application.